Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

PLAINSBORO, N.J., March 3, 2025 /PRNewswire/ -- Novo Nordisk launched "My Ozempic ® Era" today, a national campaign which spotlights the longstanding Ozempic ® patient community by sharing ...

The CEO of <strong>Novo Nordisk</strong> warned of the impact of tariffs on the pharmaceutical industry. Weight-loss drugs, including Ozempic and Wegovy, could cost ...

Danish drugmaker Novo Nordisk is prepared to enter the Indian market and other markets with its blockbuster drug Ozempic, despite losing patent exclusivity early next year. “Even as we face ...

Novo Nordisk does not provide its Australian sales data, and experts said the number of Australians taking GLP-1s to lose weight was unknown. This is despite a current shortage of Ozempic (which ...

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...

The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet demand. Overall sales of drugs like Wegovy and Ozempic could reach $150 billion ...